PMID- 19695229
OWN - NLM
STAT- MEDLINE
DCOM- 20091013
LR  - 20151119
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 388
IP  - 3
DP  - 2009 Oct 23
TI  - Angiotensin II receptor blockade improves matrix metalloproteinases/tissue 
      inhibitor of matrix metalloproteinase-1 balance and restores fibronectin 
      expression in rat infarcted myocardium.
PG  - 606-11
LID - 10.1016/j.bbrc.2009.08.073 [doi]
AB  - Matrix metalloproteinases (MMPs) and the tissue inhibitors of MMPs (TIMPs) have 
      been recognized to play a pivotal role in matrix remodeling following myocardial 
      infarction (MI). The aims of the present study were to examine the expression 
      profile of MMPs/TIMP-1 after MI and to determine whether angiotensin II receptor 
      (ATR) blockade improves MMPs/TIMP-1 balance. Compared with sham-operated rats, in 
      vivo MI-induced a significant elevation of MMP-2, MMP-3 and MMP-9 levels and a 
      marked reduction of TIMP-1 and fibronectin (FN) expressions in infarcted left 
      ventricular free wall (LVFW) and hypertrophic interventricular septum (IS) but 
      not in non-infarcted right ventricle (RV). In addition, regional MI increased 
      MMP-2, MMP-3 and MMP-9, while decreased TIMP-1 and FN in infarcted LVFW and 
      hypertrophic IS compared with the non-infarcted RV. Compared with vehicle-treated 
      MI rats, oral valsartan, but not PD123319, limited infarct size, normalized 
      MMPs/TIMP-1 balance and restored FN level. The present findings might further our 
      understanding of the regulatory mechanisms of valsartan in myocardial remodeling 
      after MI.
FAU - Yang, Dachun
AU  - Yang D
AD  - Department of Cardiology, General Hospital of PLA Chengdu Military Area Command, 
      Chengdu 610083, PR China.
FAU - Ma, Shuangtao
AU  - Ma S
FAU - Li, De
AU  - Li D
FAU - Tang, Bing
AU  - Tang B
FAU - Yang, Yongjian
AU  - Yang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090818
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Fibronectins)
RN  - 0 (Imidazoles)
RN  - 0 (Pyridines)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Tetrazoles)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 130663-39-7 (PD 123319)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*pharmacology
MH  - Animals
MH  - Fibronectins/*biosynthesis
MH  - Imidazoles/pharmacology
MH  - Male
MH  - Matrix Metalloproteinases/*metabolism
MH  - Myocardial Infarction/*metabolism/pathology
MH  - Pyridines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Angiotensin, Type 1/drug effects/*metabolism
MH  - Tetrazoles/*pharmacology
MH  - Tissue Inhibitor of Metalloproteinase-1/*metabolism
MH  - Valine/*analogs & derivatives/pharmacology
MH  - Valsartan
EDAT- 2009/08/22 09:00
MHDA- 2009/10/14 06:00
CRDT- 2009/08/22 09:00
PHST- 2009/08/05 00:00 [received]
PHST- 2009/08/13 00:00 [accepted]
PHST- 2009/08/22 09:00 [entrez]
PHST- 2009/08/22 09:00 [pubmed]
PHST- 2009/10/14 06:00 [medline]
AID - S0006-291X(09)01641-6 [pii]
AID - 10.1016/j.bbrc.2009.08.073 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2009 Oct 23;388(3):606-11. doi: 
      10.1016/j.bbrc.2009.08.073. Epub 2009 Aug 18.